

## **Supplementary - External Validation of Radiation-Induced Dyspnea Models on Esophageal Cancer Radiotherapy Patients**

**Zhenwei Shi<sup>1</sup>, Kieran Foley<sup>4</sup>, Juan Pablo de Mey<sup>2</sup>, Emiliano Spezi<sup>3</sup>, Philip Whybra<sup>3</sup>, Tom Crosby<sup>4</sup>, Johan van Soest<sup>1</sup>, Andre Dekker<sup>1</sup> and Leonard Wee<sup>1</sup>**

<sup>1</sup> Department of Radiation Oncology (MAASTRO Clinic), GROW – School for Oncology and Development Biology, Maastricht University Medical Centre, The Netherlands; <sup>2</sup> Faculty of Health Medicine and Life Sciences (FHML), Maastricht University, The Netherlands; <sup>3</sup> School of Engineering, Cardiff University, Cardiff, UK; <sup>4</sup> Velindre Cancer Centre, Cardiff, UK;

**Table 1: The performance assessment of the validated dyspnea model 1 and model 2 on the external validation cohorts V1 and V2.**

	<b>External validation cohort (V1)</b>	<b>External validation cohort (V2)</b>
<b>Incidence</b>	11%	11%
<b>AUC</b>	0.68 (95% CI: 0.55-0.76)	0.70 (95% CI: 0.58-0.77)
<b>Accuracy</b>	0.54 (95% CI: 0.47-0.61)	0.88 (95% CI: 0.84-0.92)
<b>Sensitivity</b>	0.70	0.32
<b>Specificity</b>	0.52	0.95
<b>PPV</b>	0.15	0.45
<b>NPV</b>	0.93	0.92

AUC area under curve; CI confidence interval; PPV positive predictive value; NPV negative predictive value.